CD47 recombinant proteins and antibodies

CD47 is a transmembrane glycoprotein widely expressed on the surface of various cell types, particularly tumor cells, red blood cells, and immune cells. CD47 is known as the “don’t eat me” signal because it interacts with its receptor SIRPα (signal regulatory protein α) to inhibit phagocytosis by immune cells, protecting cells from clearance by macrophages. In the tumor microenvironment, high expression of CD47 enables tumor cells to evade immune surveillance, promoting tumor growth and metastasis. As a result, CD47 has become a key target for immune evasion in tumors and a promising focus in cancer immunotherapy research.

Currently, drug development targeting CD47 focuses on two main approaches: one involves anti-CD47 monoclonal antibodies, which block the interaction between CD47 and SIRPα, relieving immune suppression and activating macrophages to phagocytose tumor cells; the other involves SIRPα antibodies, which enhance macrophage recognition of CD47 and further promote tumor cell clearance. CD47-targeted therapy is believed to enhance the immune system’s anti-tumor activity, especially in treating refractory cancers such as liver cancer, lung cancer, and hematological malignancies. In terms of drug development, several biopharmaceutical companies are advancing CD47-targeted therapies. For instance, Forty Seven (now acquired by Gilead) has developed the anti-CD47 monoclonal antibody Magrolimab, which has entered clinical trials for the treatment of hematologic cancers like acute myeloid leukemia (AML) and other malignant blood disorders. Additionally, companies like AbbVie and BMS are also working on CD47-targeted drugs, exploring their applications in solid tumors. Another biotech company, Mirati Therapeutics, is developing anti-SIRPα monoclonal antibodies as regulators of the CD47/SIRPα pathway to enhance tumor immune clearance. As research into CD47 mechanisms deepens, CD47-targeted therapies are gradually entering clinical stages, with the potential to provide significant breakthroughs in cancer treatment. Several innovative CD47-targeted drugs are currently in clinical trials, and these may offer more effective treatment options for various types of tumors in the future.

To assist in the development of CD47 targeted drugs, DIMA BIOTECH can now provide a series of spot products targeting CD47, including CD47 recombinant proteins, CD47 full-length membrane proteins, anti-CD47 monoclonal antibodies and biosimilar reference antibodies. At the same time, we can also provide systematic services, including protein/antibody customization services, antibody humanization, antibody affinity maturation, stable cell lines, etc. In addition, we have established a B cell seed bank targeting CD47, which can screen out the lead antibody molecules required by customers in just 20 days.